Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 9Recruiting 6Active not recruiting 6Unknown 2Withdrawn 1Terminated 1Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 27Gynecologic 4Genitourinary 3Breast 2Thoracic 1Sarcoma 1Other solid neoplasm 1Head & Neck 1

Conditions

Advanced Non-squamous Non-small-cell Lung Cancer 1

Interventions

Carboplatin 63Cisplatin 40Pemetrexed 38Drug Therapy 37osimertinib 22anlotinib 22Etoposide 20tislelizumab 17Radiotherapy 17Paclitaxel 17Surgical Procedures, Operative 16pembrolizumab 15toripalimab 14130-nm albumin-bound paclitaxel 14aflutinib 13Docetaxel 13Bevacizumab 12sintilimab 10Specimen Handling 10Magnetic Resonance Spectroscopy 10Injections 9durvalumab 8cemiplimab 8Radiosurgery 8Platinum 8PM 01183 8Immunotherapy 8atezolizumab 7Platinum Compounds 7Blood Specimen Collection 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × lenvatinib × Thoracic × Clear all
NCT06028633 2023-09-13

Efficacy and Safety of Nab-paclitaxel-Lenvatinib-Pembrolizumab as Second-line Treatment in Advanced NSCLC Patients

Peking University First Hospital

Phase 2 Not yet recruiting
28 enrolled
Thoracic

Advanced Non-squamous Non-small-cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡